Uterine artery ligation versus pericervical tourniquet to reduce bleeding during open myomectomy
Bilateral Uterine Artery Ligation Versus Pericervical Mechanical Tourniquet Application in Reducing Intraoperative Blood Loss During Transabdominal Myomectomy.
This trial will test whether tying the uterine arteries or using a pericervical tourniquet better reduces blood loss during open myomectomy for women with symptomatic uterine fibroids.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 25 Years to 48 Years |
| Sex | Female |
| Sponsor | Cairo University Academic / other |
| Locations | 1 site (Cairo, Al-Manial) |
| Trial ID | NCT07526311 on ClinicalTrials.gov |
What this trial studies
This is a prospective, randomized comparison of two vascular control techniques—bilateral uterine artery ligation and pericervical mechanical tourniquet—applied during elective transabdominal myomectomy. Women with symptomatic intramural fibroids (FIGO types 3–6) who meet inclusion criteria are randomized to one technique before myoma enucleation. The study measures intraoperative blood loss and surgical safety outcomes, including complications and need for transfusion. The trial is conducted at the Department of Obstetrics and Gynecology, Kasr Al‑Ainy Hospital, Cairo University.
Who should consider this trial
Good fit: Women aged 25–48 with symptomatic intramural uterine fibroids (FIGO 3–6), BMI under 35 kg/m², preoperative hemoglobin ≥10 g/dL, and scheduled for elective transabdominal myomectomy who can give informed consent.
Not a fit: Patients with submucosal, intracavitary, pedunculated, cervical, or adnexal myomas, prior uterine surgery, bleeding disorders, anticoagulant use, BMI ≥35 kg/m², or preoperative hemoglobin <10 g/dL are not eligible and therefore unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the preferred technique could reduce intraoperative blood loss, lower transfusion rates, and make myomectomy safer while preserving the uterus.
How similar studies have performed: Both uterine artery ligation and pericervical tourniquet are used in practice and small series suggest each can reduce bleeding, but few randomized head‑to‑head trials have directly compared them.
Eligibility criteria
Show full inclusion / exclusion criteria
* Inclusion Criteria: * Female participants aged 25 to 48 years * Body mass index less than 35 kg/m² * Symptomatic uterine myomas requiring surgical treatment * Intramural myomas classified as FIGO types 3 to 6 * Diagnosis confirmed by transvaginal ultrasound and/or magnetic resonance imaging * Maximum diameter of the largest myoma 20 cm or less * Scheduled for elective transabdominal myomectomy * Able and willing to provide written informed consent * Exclusion Criteria: * Submucosal, intracavitary, pedunculated subserosal, cervical, or adnexal myomas * FIGO types 0, 1, 2, 7, or 8 myomas * History of pelvic inflammatory disease or peritonitis * Previous abdominal or pelvic surgery for non-obstetric causes * Previous uterine surgery * Use of hormonal therapy within the previous 3 months * Known bleeding disorder * Use of anticoagulant or antiplatelet therapy * Preoperative hemoglobin less than 10 g/dL * Body mass index 35 kg/m² or greater * Intraoperative conversion from myomectomy to hysterectomy
Where this trial is running
Cairo, Al-Manial
- Cairo University — Cairo, Al-Manial, Egypt (Recruiting)
Study contacts
- Study coordinator: Maged Elmohamady Rashedy, MD
- Email: Magedalmohamady50@gmail.com
- Phone: 01090013685
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.